this is the responsibility of BlackRock Investment Stewardship. Principally through the work of BIS team, BlackRock meets the requirements in the Shareholder Rights Directive II (‘SRD II”) relating to engagement with public companies and other parties in the investment ecosystem. A copy of BlackRock...
Laurie has a curious attitude to correcting her work, although she has replied to oneof my less criticalcomments, she neglected to respond to the above issue (despite prompting); and for the following duplicated flow cytometry plots, she provided this dismissiveresponse: “You should reach out t...
Sanofi, Takeda, and Teva; participated in advisory boards for Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, and Takeda; provided scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol Myers Squibb, Eli Lilly,...
In this work, a nine-emitter implantable device, SonoCloud-9 (SC9, Carthera, Lyon, France), was developed to disrupt a much larger region of the peritumoral brain than tested in the FIH study for drug delivery and evaluated in a Phase I/II multicenter clinical trial in rGBM patients ...
PM reports personal fees from Sanofi during the conduct of the study; and personal fees from Celgene, Amgen, and Janssen, outside the submitted work. TM reports research support for his institution from Sanofi and Amgen. YD and M-LR are employees of Sanofi and may hold stock/shares in the...
I began to pursue the use of the femtosecond laser in cataract surgery. In my work, I met Mark Forchette, who at the time was president and CEO of Optimedica (later acquired by Abbott Medical Optics; now Johnson & Johnson Vision). He introduced me to a formidable group of ophthalmologist...
Sanofi Summer 2025 Intern - Veeva and Appian COE Bridgewater Township, NJ 🔒 Oct 25 Pacific Life Data Analytics Intern Newport Beach, CA 🔒 Oct 25 ↳ Data Engineering Intern Newport Beach, CA 🔒 Oct 25 ↳ Software Engineering Intern Newport Beach, CA 🔒 Oct 25 Northrop Grumman 2025...
Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome...
35 Markedly, Sanofi/Principia has developed an oral SM BTK inhibitor, tolebrutinib (20), which has strong brain-penetrating properties and that is currently undergoing phase III clinical trials for the treatment of MS. New data have also been released supporting its potential for the treatment ...
Conflict of Interest Disclosures: Dr Gettinger reported receiving grants and research support for trials (to Yale Cancer Center) from Bristol Myers Squibb and research support for trials (to Yale Cancer Center) from NextCure, IOVANCE, Genentech/Roche, and Takeda/Ariad outside the submitted work. Dr...